Endpoints News 生物医药· Max Bayer·· 2026-10-15AI 评分17
FDA新框架向一致性而非灵活性倾斜
New FDA framework tilts toward consistency over flexibility
AI 导读
FDA新框架向一致性而非灵活性倾斜。FDA多位时任代理领导今夏表示,评估罕见病药物时,监管灵活性并非该机构追求的标准。
正文
Then-acting FDA leaders said over the summer that regulatory flexibility wasn’t the standard they were striving for when the agency gauges rare disease drugs.
Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news